The company's platform uses proprietary and validated algorithms to select optimal neo-epitopes, addressing unmet medical needs in cancer therapy. EpiVax Therapeutics, founded in 2017, uses a world-leading technology developed over 22 years to design vaccines that activate the body's T cells to cure or prevent disease. Their pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.